COMMUNIQUÉS West-GlobeNewswire

Applied Biologics CEO and Former Marine F/A-18 Pilot Edward Britt Selected as Honorary Commander at Luke Air Force Base
24/08/2026
Former Marine Corps Captain selected to serve with leadership of the 56th Operational Medical Readiness Squadron SCOTTSDALE, Ariz., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Applied Biologics today announced that Edward Britt, [...]
Novo Nordisk A/S - share repurchase programme
24/08/2026
Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
R3 Vascular Expands Management Team with Two Senior Executives
24/08/2026
Appointments Support Accelerated Trial Enrollment, Market Development, Scalability, and Future Commercialization MOUNTAIN VIEW, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company [...]
Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
24/08/2026
SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development [...]
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
24/08/2026
BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business [...]
A Race Against Blindness Launches New Yukon Denali + Serenova Trailer Fundraiser to Help Cure Childhood Blindness
24/08/2026
One of the nonprofit’s most-loved campaigns returns with an upgraded 2026 GMC Yukon Denali, Grand Design Serenova travel trailer, and $50,000 cash—all supporting research for inherited retinal diseases GILBERT, Ariz. , [...]
WONDERLAB and United Family Healthcare | Global Health Summit 2026
24/08/2026
HONG KONG, Aug. 24, 2026 (GLOBE NEWSWIRE) -- The partnership will advance microbiome research in metabolic health, while WONDERLAB showcases SHAPE100™ research and its AKKKING™ metabolic-health formula. WONDERLAB has [...]
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
24/08/2026
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) [...]
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
24/08/2026
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED [...]
Mesoblast Financial Results and Corporate Update Webcast
24/08/2026
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
24/08/2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
24/08/2026
Company intends to accelerate the rehabilitation of Canndoc’s flagship Nir Oz facility, supporting a return to full production and the Company’s expansion in the growing German medical cannabis market NEW YORK and [...]
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
24/08/2026
Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter [...]
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
24/08/2026
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
24/08/2026
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with [...]
Felix Health launches sleep apnea care through new collaboration with MedSleep
24/08/2026
With more than one in four Canadian adults estimated to be at high risk for obstructive sleep apnea, Felix is expanding into sleep apnea care to help patients more easily access assessment and appropriate treatment. The [...]
Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year
24/08/2026
Company Achieves Record Growth Through Peak Rainy Season, with Management Confirming Even Greater Output Within Reach ANN ARBOR, Mich., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
La Commission européenne autorise TECVAYLI®▼ (teclistamab) de Johnson & Johnson associé au daratumumab dans le traitement du myélome multiple récidivant ou réfractaire, offrant ainsi une nouvelle référence thérapeutique potentielle
24/08/2026
Cette autorisation repose sur des données de Phase 3 sans précédent, démontrant une amélioration statistiquement significative de la survie sans progression et de la survie globale par rapport aux schémas thérapeutiques [...]
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
24/08/2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]

Pages